| Autor: |
Ronald A. DePinho, Y. Alan Wang, Lynda Chin, Mark J. McArthur, Christopher J. Logothetis, Patricia Troncoso, Qing Chang, Liren Li, Yanxia Shi, Zhihu Ding, Xiaolu Pan, Wantong Yao, Eun-Jung Jin, Baoli Hu, Pingping Hou, Sunada Khadka, Xiaoying Shang, Di Zhao, Tim Heffernan, Trang N. Tieu, Vandhana Ramamoorthy, Zhenglin Guo, Neelay Bhaskar Patel, Chang-Jiun Wu, Avnish Kapoor, Elsa M. Li-Ning-Tapia, Jianhua Zhang, Sujun Hua, Ramakrishna Konaparthi, Kun Zhao, Zhuangna Fang, Shan Jiang, Chia Chin Wu, Pingna Deng, Prasenjit Dey, Xin Lu, Guocan Wang |
| Rok vydání: |
2023 |
| DOI: |
10.1158/2159-8290.22530990.v1 |
| Popis: |
Supplementary Figure S1. CyTOF analysis of biological samples from Ptenpc-/-Smad4pc-/- mice (Related to Figure 2). Supplementary Figure S2. Strategy used for MDSCs Isolation (Related to Figure 3). Supplementary Figure S3. Treatment scheme for Gr-1 antibody, peptibody, and Cxcr2 inhibitor SB225002. Supplementary Figure S4. IHC staining of Ki67, CD45, Vimentin, Smooth muscle actin (SMA) and Trichrome staining of mouse prostate tissues treated with IgG control or Gr1 antibody. Supplementary Figure S5. The top 10 differentially expressed genes in Ptenpc-/-Smad4pc-/- tumors as compared to Ptenpc-/- tumors, identified by microarray analysis (n=5). Figure S6. Top 10 activated oncogenic signatures identified by GSEA analysis in Ptenpc-/- Smad4pc-/- tumors as compared to Ptenpc-/- tumors (n=5). Figure S7. Clustering of primary prostate tumors from Wallace et al into MDSC-high and MDSC-low subtypes. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
